Latest Breaking News On - Trilaciclib combined - Page 1 : comparemela.com

G1 Therapeutics, Inc. announced that mature Phase 2 results describing the positive impact of trilaciclib administered in combination with the TROP2 antibody-drug conjugate sacituzumab govitecan on.

United statesAmerican society of clinical oncologyTherapeutics incClinical oncologyPresentation detailsTrilaciclib combinedSacituzumab govitecanMetastatic triple negative breast cancerUpdated phaseEfficacy results seneviratneBreast cancer metastatic june